SDL remains a top pick in the southern premium housing space, with strong recall, expanding geographic footprint, and improving financial metrics. Its expanding launch pipeline and improving approvals position it well for volume-led growth, cash flow generation, and margin recovery in FY26
Trent remains a stellar business. However, the ask from the business is too high (from a valuation stencil). Westside seems to be showing signs of customer fatigue, while Zudio seems to be peaking in terms of unit economics. We build in 23% revenue and PBT CAGR over FY25-27 (8-10% lower than consensus). We maintain SELL on Trent with an SOTP-based TP of INR4,300/sh (incl. 60x adj P/E for the standalone operations)
The Indian PSU banking (PSB) sector, once considered structurally broken, is experiencing early signs of a secular turnaround, buttressed by a combination of governance reforms (balance sheet repair and recapitalization), modernized digital stack, and a gradual turnaround in the quality and sustainability of earnings.
Siemens Energy India Ltd (SEL) captures the maximum value among its peers as it has products/solutions covering a larger market size, viz., decarbonization, power generation, power evacuation, grid automation, EPC services, and clean energy like green hydrogen and battery storage. Over the years, this has been a highly profitable business for Siemens India which has clocked 22.6% EBITDA margin during H1FY25 (5 months)
In our view, the generic companies are unlikely to have any impact. Moreover, Sun Pharma with its specialty business (15-18% of sales) in the US may see some impact of MFN price ceiling for a few of its products like Ilumya, Winlevi, Odomzo, Cequa, which are marketed in other developed markets, whereas Sun’s other products like Levulan, Absorica, Bromsite, Xelpros, Yonsa, Sezaby, Sprinkle portfolio, and the recently-approved Leqselvi (Deuruxolitinib) are marketed only in the US.
Each of these companies has been chosen for their strong growth potential and sustainability over a 3–5-year horizon. Our selection process emphasises not only growth sustainability but also the importance of current valuations, ensuring that investors can benefit from earnings compounding, translating into stock compounding
We interacted with the Stylam Industries (Stylam) promoter. Management is targeting to double its revenue in the next 4 years. It is confident domestic sales will pick up in next 2-3 quarters. It has major plans to ramp up sales in the US market, which will accelerate the company’s growth rates. Management’s focus is to sell higher value-added products, which will improve the company’s margin profile. As per management assessment, in the next few months, the government might levy anti-dumping duty on low-cost and low-quality acrylic dumping by Chinese/Korean entities.
We continue to maintain Radico as a high-conviction BUY with a target price of INR 2,600 (52x FY27 EPS). We expect the company to deliver revenue/EBITDA/PAT CAGRs of 15%/26%/34%, respectively, over FY24-27, driven by the following factors
Leading experts have issued the chilling prophecy that the uncertainty caused by the impending elections in the USA will cause the markets to crash. We have to keep red alert and be prepared to bail out at the first sign of trouble
Saurabh Mukherjea has, for the first time, revealed the names of some of the multibaggers in his famous portfolio of ‘Little Champs’. The stocks are said to be sector leading franchises with a stellar track record of capital allocation, clean accounts & corporate governance and at the same time high growth potential
Recent Comments